ECSP10010318A - Derivado de -lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene - Google Patents

Derivado de -lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene

Info

Publication number
ECSP10010318A
ECSP10010318A EC2010010318A ECSP10010318A ECSP10010318A EC SP10010318 A ECSP10010318 A EC SP10010318A EC 2010010318 A EC2010010318 A EC 2010010318A EC SP10010318 A ECSP10010318 A EC SP10010318A EC SP10010318 A ECSP10010318 A EC SP10010318A
Authority
EC
Ecuador
Prior art keywords
derivatives
lactone
hidroxi
steroid
carboxyl
Prior art date
Application number
EC2010010318A
Other languages
English (en)
Inventor
Ulrich Klar
Rolf Bohlmann
Joachim Kuhnke
Hans Peter Muhn
Sven Ring
Jan Huebner
Katja Prelle
Steffen Borden
Frederik Menges
Thomas Frenzel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ECSP10010318A publication Critical patent/ECSP10010318A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La invención se refiere a derivados de -lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico de la fórmula química I, donde R4, R6a, R6b,R7, R15, R16a, R16b, R18 y Z tienen los significados indicados en la reivindicación 1, así como sus solvatos, hidratos, estereoisómeros y sales. La invención también se refiere al uso de estos derivados para la preparación de un medicamento para la contracepción oral y para el tratamiento de trastornos pre, peri y posmenopáu-sicos, así como a medicamentos que contienen tales derivados. Los derivados de la invención presentan un efecto gestagénico y en casos preferidos además un efecto antimineralcosrticoide y neutro a ligeramente androgénico.
EC2010010318A 2007-12-29 2010-06-29 Derivado de -lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene ECSP10010318A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063503A DE102007063503A1 (de) 2007-12-29 2007-12-29 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
ECSP10010318A true ECSP10010318A (es) 2010-08-31

Family

ID=40481980

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010318A ECSP10010318A (es) 2007-12-29 2010-06-29 Derivado de -lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene

Country Status (22)

Country Link
US (1) US8937058B2 (es)
EP (1) EP2238151A1 (es)
JP (1) JP5600068B2 (es)
KR (1) KR20100102688A (es)
CN (1) CN101910190A (es)
AR (1) AR069966A1 (es)
AU (1) AU2008342910A1 (es)
BR (1) BRPI0821922A2 (es)
CA (1) CA2710491C (es)
CL (1) CL2008003918A1 (es)
CO (1) CO6300845A2 (es)
CR (1) CR11545A (es)
DE (1) DE102007063503A1 (es)
DO (1) DOP2010000198A (es)
EC (1) ECSP10010318A (es)
IL (1) IL206379A0 (es)
PA (1) PA8809701A1 (es)
PE (1) PE20091362A1 (es)
TW (1) TW200940073A (es)
UY (1) UY31584A1 (es)
WO (1) WO2009083266A1 (es)
ZA (1) ZA201005396B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007063503A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918463A (en) 1958-06-12 1959-12-22 Searle & Co 17-carboxyalkylated 17-hydroxy-19-norandrosten-3-ones
US3194803A (en) * 1960-04-28 1965-07-13 Searle & Co Process and intermediates for the manufacture of 3-keto-delta4, 6 steroids
US3254074A (en) * 1962-04-25 1966-05-31 Merck & Co Inc Spiroxenones
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3022337A1 (de) 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPS59139400A (ja) * 1983-01-31 1984-08-10 Shionogi & Co Ltd 抗アルドステロン活性ステロイド誘導体
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3410880A1 (de) * 1984-03-21 1985-10-03 Schering AG, Berlin und Bergkamen, 1000 Berlin 17-substituierte estradiene und estratriene
DE3426771C2 (de) 1984-07-07 1997-03-20 Schering Ag 13alpha-Methylgonane, deren Herstellung und Verwendung
DE4232521A1 (de) 1992-09-22 1994-03-24 Schering Ag Gestagen wirksame 4,5;11,12-Estradiene, Verfahren zu ihrer Herstellung, diese Estradiene enthaltende Arzneimittel sowie deren Verwendung zur Herstellung von Arzneimitteln
DE4447401A1 (de) 1994-12-23 1996-07-04 Schering Ag 14,17-C¶2¶-überbrückte Steroide
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
DE102007063503A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Also Published As

Publication number Publication date
IL206379A0 (en) 2010-12-30
US20110021472A1 (en) 2011-01-27
ZA201005396B (en) 2012-01-25
US8937058B2 (en) 2015-01-20
DE102007063503A1 (de) 2009-07-02
UY31584A1 (es) 2009-08-03
CO6300845A2 (es) 2011-07-21
BRPI0821922A2 (pt) 2015-06-16
AR069966A1 (es) 2010-03-03
JP2011507924A (ja) 2011-03-10
CA2710491C (en) 2015-11-03
DOP2010000198A (es) 2010-08-31
CL2008003918A1 (es) 2010-01-15
AU2008342910A1 (en) 2009-07-09
TW200940073A (en) 2009-10-01
EP2238151A1 (de) 2010-10-13
WO2009083266A1 (de) 2009-07-09
JP5600068B2 (ja) 2014-10-01
KR20100102688A (ko) 2010-09-24
CR11545A (es) 2010-08-27
PE20091362A1 (es) 2009-10-15
CA2710491A1 (en) 2009-07-09
CN101910190A (zh) 2010-12-08
PA8809701A1 (es) 2009-07-23

Similar Documents

Publication Publication Date Title
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
DOP2011000218A (es) Derivados de sulfonamida
ECSP088774A (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricación.
CL2009000085A1 (es) Compuestos derivados de sulfonamida sustituida, modulares de receptores de bradiquinina; proceso para su preparacion; composicion farmaceutica que contiene a los compuestos; y uso en el tratamiento del dolor agudo, neuropatico o cronico, entre otros.
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
ECSP10010318A (es) Derivado de -lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene
ECSP10010317A (es) Derivado 15,16-metilen-17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
CL2008001559A1 (es) Compuestos heterociclos que contienen al menos un atomo de nitrogeno, moduladores de gamma secretasa; composiciones farmaceuticas que los comprenden; uso de los compuestos en la preparacion de medicamentos para tratar trastornos del sistema nervioso central, tal como alzheimer; y kit que incluye a la composicion farmaceutica.
CO6300840A2 (es) Derivado y-lactona de esteroide de acido 15, 16-metilen-17-hidroxi-19-nor-21-carboxilico su uso y medicamentos que contienen tal derivado
CU20100141A7 (es) Derivados de ganma-lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene
ECSP10010316A (es) Derivado de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen
CU20100138A7 (es) Derivados de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen
CU20100140A7 (es) Derivados de 15,16-metilen-17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
CU20100139A7 (es) Derivados de y-lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamentos que contienen tal derivado
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
TH104953A (th) อนุพันธ์ 17-(1'-โพรพีนิล)-17-3'-ออกซิโดเอสตรา-4-อีน-3-โอน, การใช้อนุพันธ์ดังกล่าว และผลิตภัณฑ์ยาที่มีอนุพันธ์
TH104140A (th) อนุพันธ์ 17-ไฮดรอกซี-19-นอร์-21-คาร์บอกซิลิคแอซิด-สเตอรอยด์ แกมมา-แลคโตน การใช้สารนี้และผลิตภัณฑ์ทางยาที่มีอนุพันธ์นี้อยู่ด้วย